Department of Radiotherapy, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Banshanqiao District, Hangzhou, PR China.
Clin Chim Acta. 2012 Jan 18;413(1-2):213-8. doi: 10.1016/j.cca.2011.09.026. Epub 2011 Sep 29.
To evaluate the use of cellular immunity parameters as predictors of therapy response.
Circulating lymphocytes were measued by flow cytometry in 94 nasopharyngeal carcinoma (NPC) patients following radiochemotherapy.
Significantly decreased percentage of CD3(+), CD4(+), and CD8(+) lymphocytes, significantly increased proportion of CD44(+), CD25(+), NK lymphocytes, and an increased CD4(+)/CD8(+) ratio were indicated in NPC patients as compared with healthy controls. Circulating CD44(+) lymphocytes in both the N2/N3 and III/IV groups were significantly increased as compared to the N0/N1 and I/II groups, respectively (P<0.05). A significant decrease in CD19(+) lymphocytes was observed in the III/IV group as compared with the I/II group (P<0.05). After radiochemotherapy, NPC patients had significantly (P<0.05) decreased percentages of CD4(+), CD44(+), and CD19(+) lymphocytes and a decreased CD4(+)/CD8(+) ratio, whereas the mean percentages of CD8(+) and NK lymphocytes were significantly (P<0.05) increased. However, compared with the pre-radiochemotherapy values, no significant (P>0.05) changes in CD3(+) or CD25(+) lymphocytes were observed in the NPC-treated group. Follow-up analysis indicated significantly lower DFS for patients with high CD44(+) lymphocytes compared to those with low CD44(+) lymphocytes after radiochemotherapy.
Circulating CD44(+) lymphocytes seems to be a promising criterion to predict survival in NPC patients undergoing radiochemotherapy.
评估细胞免疫参数作为治疗反应预测因子的作用。
对 94 例接受放化疗的鼻咽癌（NPC）患者进行流式细胞术检测循环淋巴细胞。
与健康对照组相比，NPC 患者 CD3(+)、CD4(+)和 CD8(+)淋巴细胞的百分比显著降低，CD44(+)、CD25(+)、NK 淋巴细胞的比例显著增加，CD4(+)/CD8(+)比值升高。N2/N3 期和 III/IV 期患者的循环 CD44(+)淋巴细胞均明显高于 N0/N1 期和 I/II 期患者（P<0.05）。与 I/II 期相比，III/IV 期患者 CD19(+)淋巴细胞显著减少（P<0.05）。放化疗后，NPC 患者 CD4(+)、CD44(+)和 CD19(+)淋巴细胞的百分比明显下降（P<0.05），CD4(+)/CD8(+)比值降低，而 CD8(+)和 NK 淋巴细胞的平均百分比明显升高（P<0.05）。然而，与放化疗前相比，放化疗后的 NPC 组 CD3(+)或 CD25(+)淋巴细胞无明显变化（P>0.05）。随访分析表明，放化疗后 CD44(+)淋巴细胞高的患者无病生存率明显低于 CD44(+)淋巴细胞低的患者。
循环 CD44(+)淋巴细胞似乎是预测 NPC 患者接受放化疗后生存的一个有前途的指标。
